Immunosyn Announces Interview of CEO Stephen D. Ferrone by 'CEOCFO Interviews & News'
LA JOLLA, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Stephen D. Ferrone, CEO and President of Immunosyn Corporation (OTC Bulletin Board: IMYN) has been featured in an exclusive interview with CEOCFO Interviews & News. The interview is posted on http://www.immunosyn.com/news-conferences.html
The interview covers topics including Immunosyn's immediate focus, its future development and its market potential, the shift in the pharmaceutical industry toward biologically-derived drugs, the science behind SF-1019, the role of Argyll Biotechnologies, LLC its strategic partner and largest shareholder, Immunosyn's financial picture, the US and European regulatory approval process as it pertains to SF-1019 trials and milestones for which the public and investors should watch.
'We are pleased to be included with CEOCFO's esteemed collection of companies. This interview offers us the opportunity to present noteworthy announcements to brokers, institutional managers and individual investors as part of our strategic market communication plan,' says Stephen D. Ferrone.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.